Advertisement

Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer

      Abstract

      Polymorphisms of the genes 5′-10′-methylenetetrahydrofolate reductase (MTHFR, 677CT and 1298AC), methionine synthase (MTR, 2756AC) and methionine synthase reductase (MTRR, 66AC) provoke variations in enzyme activity, which can lead to alterations in the metabolism of folates and in the synthesis of S-adenosyl-methionine (SAM), the most active methyl donor in the body. This could play an important role in carcinogenesis through the degree of DNA methylation and of nucleotide synthesis.
      In the present study, four polymorphisms were studied, two of the methylenetetrahydrofolate reductase gene, and the other two of methionine synthase and methionine synthase reductase. Our aim was to study the association between prostate carcinoma susceptibility and these polymorphisms. A hospital-based case–control study was conducted in 182 patients (mean age: 70.7±7.29 years) with histologically confirmed prostate carcinoma and in 205 control subjects (mean age: 70.3±7.82 years) diagnosed with benign prostatic hyperplasia (BPH). Genomic DNA was extracted from peripheral leukocytes.
      Comparison of the MTHFR CT and TT genotypes in patients and the controls revealed significant differences (0.57 vs 0.38) (OR: 2.19, 95% CI: 1.46–3.30) and (0.06 vs 0.15) (OR: 0.36, 95% CI: 0.17–0.73), respectively. No statistically significant differences were found between patients and controls with respect to the MTHFR 1298AC, the MTR 2756AC and the MTRR 66AC polymorphisms. However, among the patients, the MTR 2756 allele C was related to a high Gleason score.
      We conclude that the polymorphism MTHFR C677T is clearly related to prostatic carcinogenesis, on the contrary to the other polymorphisms studied, although the MTR 2756 allele C acts as a factor of tumor aggressiveness, this being found in tumors with high carcinogenic potential.

      Key words

      Abbreviations:

      MTHFR (methylenetetrahydrofolate reductase), MTR (methionine reductase), MTRR (methionine synthase reductase), BPH (benign prostatic hyperplasia), GSTP-1 (glutathione S-transferase)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Frost P.
        • Blom H.J.
        • Gollete P.
        • Sephhard C.A.
        • Matthews R.G.
        A candidate genetic risk factor for vascular disease.
        Nat Genet. 1996; 10: 111-113
        • Deloughery T.G.
        • Evans A.
        • Sadeghi A.
        • et al.
        Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease.
        Circulation. 1996; 94: 3074-3078
        • Van der Put N.M.
        • Gabreels F.
        • Stevens E.M.
        • et al.
        A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?.
        Am J Hum Genet. 1998; 62: 1044-1051
        • Wilson A.
        • Leclerc D.
        • Rosenblatt D.S.
        • Gravel R.A.
        Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism.
        Hum Mol Genet. 1999; 8: 2009-2016
        • Gaughan D.J.
        • Kluitjmans L.A.
        • Barbaux S.
        • et al.
        The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations.
        Atherosclerosis. 2001; 157: 451-456
        • Pereira T.V.
        • Rudnicki M.
        • Pereira A.C.
        • POmbo-de-Oliveira M.S.
        • Franco R.F.
        5,10 Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leucemia risk: a meta-analysis.
        Cancer Epidemiol Biomarkers Prev. 2006; 15: 1956-1963
        • Esteller M.
        • Garcia A.
        • Martinez-Palones J.M.
        • Xercavins J.
        • Reventos J.
        Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility.
        Carcinogenesis. 1997; 18: 2307-2311
        • Ma J.
        • Stampfer M.
        • Giovannucci E.
        Methylenetetrahydrofolate reductase polymorphism, dietary interactions and risk of colorectal cancer.
        Cancer Res. 1997; 57: 1098-1102
        • Hubner R.A.
        • Houlston R.S.
        MTHFR C677T and colorectal cancer risk: a meta-analysis of 25 populations.
        Int J Cancer. 2007; 120: 1027-1035
        • Le Marchand L.
        • Wilkens L.R.
        • Kolonel L.N.
        • Henderson B.E.
        The MTHFR C677T polymorphism and colorectal cancer: a multiethnic cohort study.
        Cancer Epidemiol Biomarkers Prev. 2005; 14: 1198-1203
        • Nelson W.G.
        • De Marzo A.M.
        • Isaacs W.B.
        Prostate cancer.
        N Engl J Med. 2003; 349: 366-381
        • Lee W.H.
        • Isaacs W.B.
        • Bova G.S.
        • Nelson W.G.
        CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker.
        Cancer Epidemiol Biomarkers Prev. 1997; 6: 443-450
        • Heijmans B.T.
        • Jolanda M.A.
        • Boer H.
        • et al.
        A common variant of the methyltetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer.
        Cancer Res. 2003; 63: 1249-1253
        • Kimura F.
        • Franke K.
        • Steinhof C.
        • et al.
        Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma.
        Prostate. 2000; 45: 225-231
        • Cicek M.
        • Nock N.
        • David C.
        • Casey G.
        • Witte J.
        Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness.
        Cancer Epidemiol Biomarkers Prev. 2004; 13: 1331-1336
        • Guelpen B.
        • Wiren S.
        • Bergh A.R.
        • Hallmans G.
        • Stattin P.E.
        • Hultdin J.
        Polymorphism of methylenetetrahydrofolate reductase and the risk of prostate cancer: a nested case–control study.
        Eur J Cancer Prev. 2006; 15: 46-50
        • Hultdin J.
        • Guelpen V.
        • Bergh A.
        • Hallmans G.
        • Stattin P.
        Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study.
        Int J Cancer. 2005; 113: 819-824
        • Chen J.
        • Giovannucci E.
        • Hankinson S.E.
        • et al.
        A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma.
        Carcinogenesis. 1998; 19: 2129-2132
        • Sharp L.
        • Little J.
        • Schofield A.C.
        • Paulidou E.
        • Cotton S.C.
        • Miedzybrozka Z.
        Folate and breast cancer: the role of polymorphisms in the methylenetetrhydrofolate reductase (MTFHR).
        Cancer Lett. 2002; 181: 65-71
        • Skibola C.F.
        • Smith M.T.
        • Kane E.
        • et al.
        Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults.
        Proc Natl Acad Sci U S A. 1999; 96: 12810-12815
        • Wiemels J.L.
        • Smith R.N.
        • Taylor G.M.
        • Eden O.B.
        • Alexander F.E.
        • Greaves M.F.
        Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia.
        Proc Natl Acad Sci U S A. 2001; 98: 4004-4009
        • Song C.
        • Xing D.
        • Tan W.
        • Wei Q.
        • Lin D.
        Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population.
        Cancer Res. 2001; 61: 3272-3275
        • Matsuo K.
        • Suzuki R.
        • Hamajina N.
        • et al.
        Association between polymorphism of folate and methionine metabolizing enzymes and susceptibility to malignant lymphoma.
        Blood. 2001; 97: 3205-3208
        • Kimura F.
        • Florl A.R.
        • Steinhoff C.
        • et al.
        Polymorphic methyl group metabolism genes in patients with transitional cell carcinoma of the urinary bladder.
        Mutat Res. 2001; 458: 49-54
        • Goode E.L.
        • Potter J.D.
        • Bigler J.
        • Ulrico C.
        Methionine synthase D919G polymorphism, folate metabolism and colorectal adenoma risk.
        Cancer Epidemiology Biomarkers Prev. 2004; 13: 157-162
        • Matsuo K.
        • Hamajima N.
        • Hirai T.
        • et al.
        Methionine synthase reductase gene A66G polymorphism is associated with risk of colorectal cancer.
        Asian Pac J Cancer Prev. 2002; 3: 353-359
        • Le Marchand L.
        • Dolon T.
        • Hankin J.
        • Kolonel L.
        • Wilkens L.
        • Seifried A.
        B-vitamin intake, metabolic genes and colorectal cancer risk.
        Cancer Causes Control. 2002; 13: 229-248
        • Kim Y.-I.
        Folate and carcinogenesis: evidence, mechanism and implications.
        J Nutr Biochem. 1999; 10: 66-88
        • Ulvik A.
        • Ueland P.M.
        Single nucleotide polymorphism (SNP) genotyping in unprocessed whole blood and serum by real-time PCR: application to SNPs affecting homocysteine and folate metabolism.
        Clin Chem. 2001; 47: 2050-2053
        • Yegnasubramanian S.
        • Kowalski J.
        • Gonzalgo M.
        • et al.
        Hypermethylation CpG islands in primary and metastatic human prostate cancer.
        Cancer Res. 2004; 64: 1975-1986
        • Pavillard V.
        • Drbal A.A.
        • Swaine D.J.
        • Phillips R.M.
        • Double J.A.
        • Nicolaou A.
        Analysis of cell-cycle kinetics and sulfur amino acid metabolism in methionine-dependent tumor cell lines; the effect of homocysteine supplementation.
        Biochem Pharmacol. 2004; 67: 1587-1599
        • Stankova J.
        • Shang J.
        • Rozen R.
        Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo.
        Clin Cancer Res. 2005; 11: 2047-2052
        • Zingg J.M.
        • Jones P.A.
        Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis.
        Carcinogenesis. 1997; 18: 869-882
        • Ryan B.M.
        • Molloy A.M.
        • McManus R.
        • et al.
        The methylenetetrahydrofolate reductase (MTHFR) gene in colorectal cancer: role in tumor development and significance of allelic loss in tumor progression.
        Int J Gastrointest Cancer. 2001; 30: 105-111
        • Singal R.
        • Ferdinand L.
        • Das P.M.
        • Reis I.M.
        • Schlesselman J.J.
        Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk.
        Int J Oncol. 2004; 25: 1465-1471
        • Shrubsole M.
        • Gao T.G.
        • Cai Q.
        • et al.
        MTR and MTRR polymorphisms dietary intake and breast cancer risk.
        Cancer Epidemiol Biomarkers Prev. 2006; 15: 586-588